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Background:With the publication of the 2014 Focused Update of the Canadian Cardiovascular Society Guidelines
for theManagement of Atrial Fibrillation, the Canadian Cardiovascular Society Atrial Fibrillation Guidelines Commit-
tee has introduced a new triage and management algorithm; the so-called “CCS Algorithm”. The CCS Algorithm is
based upon expert opinion of the best available evidence; however, the CCS Algorithm has not yet been validated.
Accordingly, the purpose of this study is to evaluate the performance of the CCS Algorithm in a cohort of real
world patients.
Methods:We compared the CCS Algorithmwith the European Society of Cardiology (ESC) Algorithm in 172 hospital
inpatients who are at risk of stroke due to non-valvular atrial ﬁbrillation in whom anticoagulant therapy was being
considered.
Results: The CCS Algorithm and the ESC Algorithm were concordant in 170/172 patients (99% of the time). There
were two patients (1%) with vascular disease, but no other thromboembolic risk factors, which were classiﬁed as
requiring oral anticoagulant therapy using the ESC Algorithm, but for whom ASA was recommended by the CCS
Algorithm.
Conclusions: The CCS Algorithm appears to be unnecessarily complicated in so far as it does not appear to provide
any additional discriminatory value above and beyond the use of the ESC Algorithm, and its use could result in
under treatment of patients, speciﬁcally female patients with vascular disease, whose real risk of stroke has been
understated by the Guidelines.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The Canadian Cardiovascular Society Guidelines Committee has
recently published the 2014 Focused Update of the Canadian Cardiovas-
cular SocietyGuidelines for theManagement of Atrial Fibrillation [1] (the
Guidelines). A fundamental element of the Guidelines is a risk stratiﬁca-
tion andmanagement algorithm, the purpose of which is to recommend
an antithrombotic strategy that is accordant with an individual patient's
risk of stroke.
The development of a triage and management algorithm has been an
evolutionary process. The 2010 Canadian Cardiovascular Society Atrial
Fibrillation Guidelines [2] initially recommended the use of the CHADS2
Score [3] to estimate stroke risk. This decision was based upon its
“simplicity, familiarity and extensive validation” [2]. The Focused 2012
Update of the Canadian Cardiovascular Society Atrial Fibrillation Guide-
lines [4] subsequently utilized a modiﬁed version of the CHA2DS2-VASc
Score [5]. These Guidelines recognized that patients with a CHA2DS2-
VASc Score of 0 were at very low risk of stroke, and therefore did notck Street, Kingston, Ontario K7L
4749.
aye).
land Ltd. This is an open access article urequire treatment with any antithrombotic therapy. The Guidelines fur-
ther noted that patients with a CHADS2 Score of 0 were not necessarily
at low risk of stroke [6], and those patients with a CHADS2 Score of 0,
but a CHA2DS2-VASc Score of 1 or 2 should be treated with ASA or oral
anticoagulation (OAC), as appropriate.
With the publication of the 2014 Focused Update of the Canadian
Cardiovascular Society Guidelines for theManagement of Atrial Fibrilla-
tion [1], the Canadian Cardiovascular Society (CCS) Atrial Fibrillation
(AF) Guidelines Committee has introduced a new triage and manage-
ment algorithm; the so-called “CCS Algorithm” (see Fig. 1). The two
key deviations from the previous iteration of the Guidelines are the
exclusion of female sex from the CCS Algorithm, and the demotion of
vascular disease as a thromboembolic risk factor. The rationale for the
decision tomodify the algorithmwas based upon a review of the Danish
National Patient Registry [7], which showed that females with no other
thromboembolic risk factors have a 0.9% annual risk of stroke, and that
patientswith vascular disease, but noother thromboembolic risk factors
have a 1.4% annual risk of stroke.
In contrast, the European Society of Cardiology Guidelines (ESC) for
the Management of Atrial Fibrillation [8] continues to endorse the use of
the CHA2DS2-VASc Score as the principle determinant in the decision to
recommend treatment with OAC therapy. Speciﬁcally the ESC Guidelinesnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. The “CCS Algorithm”.
Adapted from the 2014 Focused Update of the Canadian Cardiovascular Society Guidelines
for the Management of Atrial Fibrillation [1].
Assessed for eligibility
n = 436
Did not meet the inclusion criteria
- 51 had AF due to a reversible cause
- 41 required anticoagulation with warfarin
- 99 had cognitive impairment
- 29 had communication difficulties
n = 220
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Completed the study
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Enrolled in the study
n = 186
Fig. 2. Schematic representation of patient enrollment.
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a CHA2DS2-VASc Score = 0, and female patients with a CHA2DS2-VASc
Score = 1, and OAC therapy for all other patients (i.e. for all patients
with a CHA2DS2-VASc Score of ≥1, except for female patients with a
CHA2DS2-VASc Score of 1). This ESC Algorithm is simple and familiar,
and has been extensively validated.
It is important to acknowledge, that while the new CCS Algorithm is
based upon expert opinion of the best available evidence, it has not yet
been validated prior to publication. Accordingly, the purpose of this
study is to evaluate the performance of the CCS Algorithm in real
world patients. Speciﬁcally, we intend to compare the CCS Algorithm
with the ESC Algorithm in a cohort of patients who are at risk of stroke
due to non-valvular atrial ﬁbrillation.
2. Methods
2.1. Participants
Hospital inpatientswith documented non-valvular atrialﬁbrillation/
ﬂutter (AF) in whom anticoagulant therapy was being considered were
recruited from Kingston General Hospital, located at Queen's University
in Kingston, Ontario. Patients were eligible for the study if they had new
onset or known AF that was documented on a 12 Lead ECG. Patients
were excluded if they had rheumatic heart disease (moderate or severe
mitral stenosis), AF due to a reversible cause (peri-operative, thyrotox-
icosis), or conditions other than AF that required anticoagulation (pros-
thetic heart valves, pulmonary embolism). Patients were also excluded
if they had a cognitive impairment that, in the judgment of the investi-
gator, resulted in an inability to follow study procedures, or if they were
not ﬂuent in the English language. Ethics approval was obtained from
the Research Ethics Board at Queen's University.
2.2. Data collection
The following details were abstracted from the patient chart and
conﬁrmed through verbal interview with the patient: atrial ﬁbrillationhistory (new onset versus known), atrial ﬁbrillation type (paroxysmal
versus persistent), and warfarin use.
After obtaining written informed consent, we then interviewed pa-
tients using an iPad questionnaire, “AFib Patient Kiosk” [9]. Individual
patients interacted with the iPad directly, and the research assistant
remained at the patient's side to answer questions and to provide assis-
tance where necessary. The order of the questionnaire was standard-
ized. Patients ﬁrst provided demographic information (age, sex, and
ethnicity) using a multiple choice question format. Next, a personal
health history was obtained in order to determine the CHA2DS2-
VASc12 (congestive heart failure, hypertension, age, diabetes, previous
stroke/TIA, vascular disease, and sex) Score.
2.2.1. Statistical analysis
Statistical analysis was performed using SPSS (version 17, SPSS Inc.,
Chicago, IL) and statistical signiﬁcance was established a-priori at α=
0.05. Descriptive data in addition to the CHA2DS2-VASc Score were tab-
ulated for the study cohort. The sample was further divided based upon
the presence or absence of vascular disease and was analyzed with one
way ANOVA or Chi-square analysis dependent upon the data type.
3. Results
Fig. 2 represents a schematic of the study design. A total of 436 con-
secutive hospital inpatients were screened for entry into the study be-
tween May, 2012 and August, 2012. Of those, 220 patients did not
meet eligibility criteria and were excluded, leaving 216 patients who
were eligible for inclusion in the study. Reasons for exclusion included
AF due to a reversible cause (n = 51), presence of other conditions
that required anticoagulationwithwarfarin (n= 41), cognitive impair-
ment (n=99) and communication difﬁculties (n=29). Thirty patients
declined to participate in the study, and 14 patients withdrew from the
study part way through completing the questionnaire, leaving 172
patients on whom the primary analysis was performed.
3.1. Patient characteristics
The patient characteristics of the study participants are reported in
Table 1. The average age of the study participants was 73 ± 12 years.
Table 2
Patient classiﬁcation using the ESC Algorithm (CHA2D2-VASc Score) and the “CCS
Algorithm”.
Therapy n (%) Male Female
ESC Algorithm
CHA2DS2-VASc Score ≥ 1a OAC 161 (94%) 106 55
CHA2DS2-VASc Score = 0b No therapy 11 (6%) 10 1
CCS Algorithm (progressing through algorithm)
Age ≥65 OAC 131 (76%) 82 49
CHDS OAC 28 (16%) 22 6
Vascular disease ASA 2 (1%) 2 0
No therapy No therapy 11 (6%) 10 1
*OAC= oral anticoagulant therapy. CHDS = CHF, Htn, diabetes, stroke/TIA.
a Excluding female patients with a CHA2DS2-VASc Score of 1.
b Including female patients with a CHA2DS2-VASc Score of 1.
20 S.A. LaHaye et al. / IJC Heart & Vasculature 7 (2015) 18–2178% of patients had a known history of AF, and 59% of patients were
already on warfarin. The mean CHA2DS2-VASc Score was 3.5 ± 2.0,
representing an annual absolute risk of stroke of 6.3%.
3.2. Patient classiﬁcation
Table 2 illustrates the classiﬁcation of patients using either the ESC
Algorithm or the CCS Algorithm. 10 out of 172 patients (5.8%) had a
CHA2DS2-VASc Score of 0, while there was one female patient (0.6%)
with a CHA2DS2-VASc Score of 1. Accordingly 11 out of 172 patients
(6%) were allocated to No Therapy using the ESC Algorithm. Conversely,
161 out of 172 patients (94%) have a CHA2DS2-VASc Score ≥1 (except-
ing the single female patientwith a CHA2DS2-VASc Score of 1), andwere
therefore allocated to therapy with OAC. Progressing through the CCS
Algorithm, 131 out of 172 patients (76%) were aged ≥65 years of age,
while 28 out of the remaining 40 patients (16%) had one or more of
the following “CHDS” risk factors: prior stroke or TIA, hypertension,
heart failure or diabetes mellitus. Accordingly 159 out of 172 patients
(92%) were allocated to therapy with OAC using the CCS Algorithm. 2
out of 172 patients (1%) had vascular disease as their sole thromboem-
bolic risk factor, and these two patients were allocated to therapy with
ASA using the CCS Algorithm. 11 patients (6%) were allocated to No
Therapy using the CCS Algorithm, of which one patient was female.
Table 3 presents the contingency table results. 159 out of 172
patients (92%) were recommended OAC therapy by both the ESC Algo-
rithm and the CCS Algorithm. 11 out of 172 patients (6%) were recom-
mended No Therapy by both the ESC Algorithm and the CCS Algorithm.
In total, the ESC Algorithm and the CCS Algorithm were concordant in
170/172 patients (99% of the time). There were two patients (male
sex with CHA2DS2-VASc Score = 1 due to the presence of vascular
disease, but no other thromboembolic risk factors) who were classiﬁed
as requiring OAC therapy using the ESC Algorithm, but for whom ASA
was recommended by the CCS Algorithm.
The patient characteristics were then analyzed by vascular disease
status (see Table 4). Patients with vascular disease were older (75 ±
10 versus 70 ± 13 years, p = 0.007) than patients without vascular
disease, and there was a trend towards a greater proportion of patients
with vascular disease being aged ≥75 years (54% versus 41%, p =Table 1
Patient characteristics.
Demographics n = 172
Age (years) 73 ± 12
Ethnicity
Caucasian 164 (95%)
Atrial ﬁbrillation history
New onset 38 (22%)
Known 134 (78%)
Atrial ﬁbrillation type
Paroxsymal 62 (36%)
Persistent 72 (42%)
Permanent 52 (30%)
Warfarin 102 (59%)
CHA2DS2-VASc score mean 3.5 ± 2.0
Congestive heart failure 37 (22%)
Hypertension 102 (59%)
Age ≥75 81 (47%)
Diabetes mellitus 49 (29%)
Stroke, TIA or thromboembolism 38 (22%)
Vascular disease 79 (46%)
Coronary artery disease 70 (41%)
Angina 32 (19%)
Previous myocardial infarction 42 (24%)
Previous PCI 20 (12%)
Previous CABG 22 (13%)
Peripheral arterial disease 26 (15%)
Age 65–74 50 (29%)
Female sex 56 (34%)0.076). Patients with vascular diseaseweremore likely to have a history
of heart failure (33% versus 12%, p = 0.001), and the mean CHA2DS2-
VASc Score was signiﬁcantly higher in patients with vascular disease
than in patients without vascular disease (4.4 ± 1.9 versus 2.8 ± 1.7,
p b 0.001).
4. Discussion
The Canadian Cardiovascular Society Atrial Fibrillation Guidelines
Committee has introduced the “CCS Algorithm” in the 2014 Focused
Update of the Canadian Cardiovascular Society Guidelines for the
Management of Atrial Fibrillation. This represents an attempt to further
reﬁne the risk stratiﬁcation, and treatment of patients with non-
valvular atrial ﬁbrillation. The CCS Algorithm has not yet been validated
prior to publication, and as such, we set out to evaluate the performance
of the CCS Algorithm in real world patients by comparing the CCS
Algorithm with the ESC Algorithm in a cohort of patients who are at
risk of stroke due to non-valvular atrial ﬁbrillation. The results of our
study show that, for the vast majority (99%) of patients, there is no
difference in recommended therapy between the CCS Algorithm and
the ESC Algorithm.
There are, however, two key patient populations that distinguish the
CCS Algorithm from the ESC Algorithm; patients with vascular disease
but no other thromboembolic risk factors (CHA2DS2-VASc Score = 1),
and female patientswith vascular disease, but no other thromboembolic
risk factors (CHA2DS2-VASc Score = 2).
In our cohort of patients, therewere only twopatients (1%)with vas-
cular disease but no other thromboembolic risk factors. We found that
patients with vascular disease were older, and were more likely to
have a history of heart failure than patients without vascular disease.
These results are concordant with the Danish National Patient Registry
[10], where only 508 out of the 87,202 patients (0.6%) were identiﬁed
as having vascular disease without any other thromboembolic risk
factors. In this same study, patients with vascular disease were found
to be older, and were more likely to have heart failure, hypertension,
diabetes, and previous thromboembolism. As a result, in patients with
atrial ﬁbrillation, it is very unlikely that vascular disease will occur in
isolation of other thromboembolic risk factors.
The Guidelines Committee authors recommended the use of ASA for
patients with vascular disease without any other thromboembolic riskTable 3
Contingency table results.
CCS Algorithm Total
No therapy ASA OAC
ESC algorithm No therapy 11 0 0 11
OAC 0 2 159 161
Total: 11 2 159 N = 172
*OAC= Oral anticoagulant therapy.
Table 4
Patient characteristics by vascular disease status.
Vascular disease
Absent Present p Value
(n = 93) (n = 79)
Demographics
Age (years) 70 ± 13 75 ± 10 0.007*
Ethnicity
Caucasian 88 (95%) 76 (96%) 0.624
Atrial ﬁbrillation history
New onset 19 (20%) 19 (24%) 0.568
Known 74 (80%) 60 (76%)
Atrial ﬁbrillation type
Paroxysmal 41 (44%) 21 (27%) 0.027*
Persistent 13 (14%) 7 (9%)
Permanent 20 (22%) 32 (41%)
Warfarin 52 (56%) 50 (63%) 0.326
CHA2DS2-VASc score mean 2.8 ± 1.7 4.4 ± 1.9 b0.001*
Congestive heart failure 11 (12%) 26 (33%) 0.001*
Hypertension 51 (55%) 51 (65%) 0.196
Age ≥75 38 (41%) 43 (54%) 0.076
Diabetes mellitus 24 (26%) 25 (32%) 0.398
Stroke, TIA or thromboembolism 20 (22%) 18 (23%) 0.840
Vascular disease 79 (100%)
Coronary artery disease 70 (89%)
Angina 32 (41%)
Previous myocardial infarction – 42 (53%) –
Previous PCI 20 (25%)
Previous CABG 22 (28%)
Peripheral arterial disease 26 (33%)
Age 65–74 27 (29%) 23 (30%) 0.991
Female sex 31 (33%) 25 (32%) 0.814
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ease but no other thromboembolic risk factors. It is important to note,
that this ﬁgure that was quoted was for male patients with vascular
disease but no other thromboembolic risk factors [7]. The annual stroke
rate for female patients with vascular disease but no other thromboem-
bolic risk factors is actually 2.0–2.9% [7]. This is higher than the risk of a
patient with hypertension as their sole thromboembolic risk factor
(1.6% annual stroke risk [7]), for which OAC is currently recommended
by theGuidelines. Arguably these female patients are at sufﬁciently high
risk to justify the use of OAC in preference to ASA. This position is sup-
ported by the results of the AVERROES Study [11], which showed that
apixaban reduced the risk of stroke by 54% compared to ASA with no
increase in major bleeding. As such the routine use of apixaban, in pref-
erence to ASA, in female patients with vascular disease, but no other
thromboembolic risk factors, would be expected to reduce the annual
absolute risk of stroke by 1.1–1.6% with a number needed to treat
(NNT) of 13–19 female patients over ﬁve years.
As noted by the Canadian Cardiovascular Society Atrial Fibrillation
Guideline committee authors, utilizing a simple algorithm is of para-
mount importance, since the limiting factor to an algorithm's success is
adoption by clinicians. The simple reality is that if a physician is not able
to remember the algorithm, they are not likely to use it. In this regard, it
would appear that the CCS Algorithm is unnecessarily complicated in so
far as it does not appear to provide any additional discriminatory value
above and beyond the use of the dichotomous ESC Algorithm, which is
simple, and easily remembered. Further, use of the CCS Algorithm could
result in under treatment of patients, speciﬁcally female patients with
vascular disease, whose real risk of stroke has been understated by the
Guidelines.5. Conclusion
The CCS Algorithm, as proposed by the CCS AF Guideline Committee,
does not appear to be any better in the real world setting than simply
using the ECS Algorithm. Unlike the CCS Algorithm, the ESC Algorithm
is familiar to most clinicians, and can be easily remembered and
employed to dichotomize patients into Low Risk (CHA2DS2-VASc
Score = 0, and female patients with a CHA2DS2-VASc Score = 1) for
thromboembolism, who require No Therapy, or High Risk (CHA2DS2-
VASc Score of ≥1, except for female patients with a CHA2DS2-VASc
Score of 1) for thromboembolism, who do require OAC Therapy. In the
opinion of the authors, it is ill advised to recommend ASA in preference
to apixaban for patients (male or female, but especially female) with
vascular disease as their sole thromboembolic risk factor.
Limitations
This study was conducted on hospital inpatients. As such the ﬁnd-
ings of this study may not be able to be extrapolated to the outpatient
setting. However, the results of the Danish National Patient Registry
[7] appear to be concordant with the results of the present study, and
therefore, the results of this study can likely be extrapolated to the
entire atrial ﬁbrillation population.
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